MarkDKochenderferMD

Oncology • Roanoke, VA

Assistant Professor, Internal Medicine, VA Tech Carilion Sch of Med

Join to view full profile

Dr. Kochenderfer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kochenderfer's full profile

Already have an account?

Office
2013 Jefferson St SW
Fl 2
Roanoke, VA 24014
Phone+1 540-586-5770

Fax+1 540-586-3552

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1999 - 2002
West Virginia University School of MedicineClass of 1999

Certifications & Licensure

VA State Medical License 2008 - 2026
NC State Medical License 1999 - 2009
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Start of enrollment: 2021 May 07
Terminated
Phase 2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

8 citations
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino
Journal for Immunotherapy of Cancer. 2024-03-13
65 citations
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov
Journal of Clinical Oncology. 2021-03-20
18 citations
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina
Clinical Genitourinary Cancer. 2020-12-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member